Supplementary Materials

The PDF file includes:

  • Fig. S1. Adult Fmr1 KO LEH rats exhibit deficits in OPCR.
  • Fig. S2. Object exploration time during the test phase of spontaneous recognition tasks does not differ between genotypes.
  • Fig. S3. Rationale of lovastatin treatment in FXS.
  • Fig. S4. Lovastatin has negligible effect on the weight gain of rats.
  • Fig. S5. Object exploration time during the test phase of spontaneous recognition tasks does not differ between genotypes with or without lovastatin treatment.
  • Fig. S6. WT and Fmr1 KO rats perform equally well in OR and OCR tasks throughout development with control and lovastatin diets.
  • Fig. S7. Fmr1 KO LEH rats exhibit age-specific increase of group I mGluR-LTD in CA1 of the hippocampus.
  • Table S1. Statistical results from one-sample t tests and post hoc two-sample t tests for object exploration tasks throughout development in WT and Fmr1 KO rats.
  • Table S2. Statistical results from two-way ANOVA of exploration times in object exploration tasks throughout development in WT and Fmr1 KO rats.
  • Table S3. Statistical results from one-sample t tests for object exploration tasks throughout development in WT and Fmr1 KO rats with or without lovastatin treatment.
  • Table S4. Statistical results from post hoc two-sample t tests for object exploration tasks throughout development in WT and Fmr1 KO rats with or without lovastatin treatment.
  • Table S5. Statistical results from two-way ANOVA of exploration times in object exploration tasks throughout development in WT and Fmr1 KO rats with or without lovastatin treatment.
  • Table S6. Statistical results from adult object exploration tasks, effect of lovastatin on food intake/weight gain, hippocampal basal protein synthesis, and synaptic plasticity data.
  • Table S7. LME model distribution tests of behavioral data.
  • Table S8. LME modeling results of WT and Fmr1 KO object exploration tasks throughout development.
  • Table S9. LME modeling results of WT and Fmr1 KO object exploration tasks throughout development with or without lovastatin treatment.
  • Legend for data file S1

[Download PDF]

Other Supplementary Material for this manuscript includes the following: